BioSpace News Archive

Boehringer Ingelheim and Veeva Systems today announced Boehringer Ingelheim’s selection of Veeva Development Cloud to drive end-to-end processes and seamless information sharing for greater speed in the delivery of innovative therapies.

Lipocine Inc. announced today that Antares Pharma, Inc. issued a press release announcing that the U.S. Food and Drug Administration (“FDA”) has approved TLANDO™.

European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) with Chemotherapy as Neoadjuvant Treatment for Resectable Non-Small Cell Lung Cancer.

Enanta Pharmaceuticals, Inc . today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for EDP-235, its coronavirus 3CL protease inhibitor (also known as the main coronavirus protease.

Today, the Cystic Fibrosis Foundation announced an award to Eloxx Pharmaceuticals Inc. for up to $15.9 million in additional funding to support the expansion of its ongoing ELX-02 clinical program focused on developing therapies for people with CF who have nonsense mutations.

Ribon Therapeutics today announced the first patient has been dosed in the Phase 1b/2 study of RBN-2397 in combination with the anti-PD-1 checkpoint inhibitor therapy, pembrolizumab, in patients with squamous cell carcinoma of the lung (SCCL).

Rocket Pharmaceuticals, Inc. today announces that Kinnari Patel, Pharm.D., MBA, President and Chief Operating Officer, will deliver a virtual company presentation at the Guggenheim 3rd Annual Genomic Medicines and Rare Disease Conference on Friday, April 1 at 8:00 a.m. ET.

Recordati Rare Diseases Announce Publication in T he Journal of Clinical Endocrinology & Metabolism of the Phase III LINC 4 Study Confirming Efficacy and Safety of ISTURISA ® (osilodrostat) in Patients With Cushing’s Disease, The LINC 4 study demonstrated superiority of ISTURISA ® (osilodrostat) over placebo in achieving cortisol control during the 12-week, double-blind, randomized phase (77% vs 8%, P <0.0001). ISTURISA provided rapid and s

Taysha Gene Therapies, Inc. today announced the initiation of clinical development of TSHA-102 for the treatment of Rett syndrome under a recently approved Clinical Trial Application (CTA) by Health Canada.

Orphazyme A/S announces an update to the Company’s Financial Calendar for 2022, following that the Danish Business Authority upon request from the Company has approved to extend the deadline for the Company’s filing of its annual report for the financial year ended December 31, 2021, following the in-court restructuring proceedings of the Company (please see company announcements no. 10/2022 and 11/2022).